EOLS News and Press, Evolus Inc. From 08/01/22

Evolus ( NASDAQ: EOLS ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$0.24 (+22.6% Y/Y) and the consensus Revenue Estimate is $36.65M (+40.4% Y/Y). Over the last 3 months, EPS estimates have see...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its second quarter 2022 financial results and provide a business update on Tuesday, August 2, 2022, before the U.S....

Promotion designed to increase adoption of Jeuveau ® among injectors and patients by offering consumers $160 off Jeuveau ® treatments at participating practices Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focus...

Evolus (NASDAQ:EOLS) shares are up 5.3% in early trading on Wednesday after Needham started off coverage on this medical aesthetic company with a Buy Rating. Analyst Serge Belanger has set a price target of $18 on Evolus, citing it as a "aesthetics emerging star." That implies a pot...

100% of millennials achieved greater than 1-point improvement on the Glabellar Line Scale on days 7, 14 and 30 100% of millennials were satisfied or very satisfied with treatment on days 7 and 30 Jeuveau ® found to be well-tolerated by both millennials a...

Jeuveau ® Recognized as Single Most Successful New Aesthetic Product Launched Since 2019 Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today celebrates the three-year anniversa...

Gainers: Charge Enterprises (CRGE) +8%. Freightcar America (RAIL) +8%. Microvast Holdings (MVST) +7%. Chindata Group Holdings  (CD) +6%. Infinera Corporation (INFN) +6%. Losers: Global-E Online  (GLBE) -27%. HighPeak Energy (HPK) -9%. Electronic Arts  (EA) -5%. Cullin...

Evolus (NASDAQ:EOLS) stock rose ~11% May 11 after the company's Q1 results beat analysts' estimates on May 10 post-market. The performance beauty company — which makes Jeuveau, a rival product of AbbVie's Botox for frown lines — saw its total net revenues rise by ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference. An audio webcast of ...

Evolus, Inc. (EOLS) Q1 2022 Earnings Conference Call May 10, 2022, 04:30 PM ET Company Participants David Erickson - Vice President-Investor Relations David Moatazedi - President and Chief Executive Officer Lauren Silvernail - Chief Financial Officer and Executive Vice President, Corporate De...